Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: Results of a multicenter study

Supportive Care in Cancer

Volumn 17, Issue 1, 2009, Pages 91-98

  Schwartzberg, Lee S ^a   Stepanski, Edward J ^a   Walker, Mark S ^a   Mathias, Susan ^b   Houts, Arthur C ^a   Fortner, Barry V ^a  

^a Accelerated Community Oncology Research Network   (United States)

^b Ovation Research Group   (United States)

Author keywords

Cetuximab; Chemotherapy; Infusion reaction; Monoclonal antibody; Rituximab

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPYRETIC AGENT; CETUXIMAB; HISTAMINE H1 RECEPTOR ANTAGONIST; NARCOTIC ANALGESIC AGENT; RITUXIMAB; STEROID;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CAREGIVER; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CONSCIOUSNESS; DISEASE SEVERITY; DIZZINESS; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FLUSHING; HEAD AND NECK CANCER; HEADACHE; HEALTH CARE COST; HUMAN; HYPOTENSION; INFUSION REACTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MANPOWER; METASTASIS; MULTICENTER STUDY; MYALGIA; ODYNOPHAGIA; OUTPATIENT CARE; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PREMEDICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RHINITIS; RIGOR; SAMPLING; SIDE EFFECT; SPEECH DIFFICULTY; SWELLING; SYNCOPE; TASK PERFORMANCE; THORAX PAIN; TIME; TREATMENT DURATION; URTICARIA; WHEEZING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAREGIVERS; DRUG DELIVERY SYSTEMS; FEMALE; HEALTH CARE COSTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME AND MOTION STUDIES; UNITED STATES;

EID: 57849108928     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0474-5     Document Type: Article

References (16)

1. J Bernier 2006 Cetuximab in the treatment of head and neck cancer Expert Rev Anticancer Ther 6 1539 1552
2. RJ Cersosimo 2003 Monoclonal antibodies in the treatment of cancer, part 2 Am J Health Syst Pharm 60 1631 1641
3. RJ Cersosimo 2003 Monoclonal antibodies in the treatment of cancer, part 1 Am J Health Syst Pharm 60 1531 1548
4. CH Chung B Mirakhur E Chan QT Le J Berlin M Morse 2008 Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose N Engl J Med 358 1109 1117
5. BV Fortner K Tauer L Zhu TA Okon K Moore D Templeton 2004 Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities BMC Cancer 4 22
6. Genetech (2005). Drug label for rituxan, vol 2007. Genetech
7. SBAU Green JF McCoy KP Burns AC Smith 1982 Accuracy of observational data with whole interval, partial interval, and momentary time-sampling recording techniques J Behav Assess 4 103 118
8. ImClone and Bristol-Myers Squibb (2005) ImClone and Bristol-Myers Squibb Erbitux drug label, vol 2007. ImClone and Bristol-Myers Squibb, Princeton, NJ
9. G Kohler C Milstein 2005 Continuous cultures of fused cells secreting antibody of predefined specificity. 1975 J Immunol 174 2453 2455
10. National Cancer Institute (2003) Common terminology criteria for adverse events v3.0 (ctc). National Cancer Institute, Oxford
11. D Pelletier C Duffield 2003 Work sampling: valuable methodology to define nursing practice patterns Nurs Health Sci 5 31 38
12. GL Plosker DP Figgitt 2003 Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia Drugs 63 803 843
13. S Rajpal AP Venook 2006 Targeted therapy in colorectal cancer Clin Adv Hematol Oncol 4 124 132
14. M Thomas 2005 Cetuximab: adverse event profile and recommendations for toxicity management Clin J Oncol Nurs 9 332 338
15. C Vizcarra D Belcher 2006 Management of the patient receiving parenteral biologic therapy J Infus Nurs 29 63 71
16. SF Wong 2005 Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer Clin Ther 27 684 694